Page last updated: 2024-12-10

toremifene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3005573
CHEMBL ID1655
CHEBI ID9635
SCHEMBL ID7465
MeSH IDM0026287

Synonyms (88)

Synonym
BIDD:PXR0202
BIDD:GT0211
AC-1751
BIDD:ER0222
AKOS005559276
AB00698360-09
AB00698360-10
estrimex
gtx-006
2-({4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-n,n-dimethylethanamine
2-(para-((z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethylamine (iupac)
z-toremifene
toremifenum [latin]
toremifene [inn:ban]
(z)-2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethanamine
gtx 006
toremifeno [spanish]
farestone
ethanamine, 2-(4-((1z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethyl-
ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethyl-, (z)-
CHEBI:9635 ,
toremifenum
toremifeno
2-{4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-n,n-dimethylethanamine
C08166 ,
toremifene
89778-26-7
DB00539
HMS2090B22
D08620
toremifene (inn)
2-[4-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-n,n-dimethylethanamine
j33.157k ,
toremiphene
CHEMBL1655
chlortamoxifen
STK626445
A843306
2-[4-[(z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]-n,n-dimethyl-ethanamine
NCGC00160530-02
{2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine
unii-7nfe54o27t
7nfe54o27t ,
ccris 8745
toremifene base
HY-B0005A
CS-1268
toremifene [iarc]
ethanamine, 2-(4-((1z)-4-chloro-1,2-diphenyl-1-buten-1-yl)phenoxy)-n,n-dimethyl-
toremifene [inn]
toremifene [who-dd]
toremifene [vandf]
toremifene [ema epar]
toremifene [mi]
gtpl4325
2-[4-[(z)-4-chloro-1,2-di(phenyl)but-1-enyl]phenoxy]-n,n-dimethylethanamine
CCG-220952
DL-519
AB00698360-07
SCHEMBL7465
cid_3005572
2-[4-[(z)-4-chloranyl-1,2-diphenyl-but-1-enyl]phenoxy]-n,n-dimethyl-ethanamine;2-oxidanylpropane-1,2,3-tricarboxylic acid
bdbm58492
2-[4-[(z)-4-chloro-1,2-diphenyl-but-1-enyl]phenoxy]ethyl-dimethyl-amine;citric acid
AB00698360_12
AB00698360_11
DTXSID3023689 ,
mfcd00801070
(2-{4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine
SR-01000763502-5
t0r ,
MRF-0000351
SBI-0206902.P001
HMS3714P06
2-{4-[(1z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-n,n-dimethylethan-1-amine
Q3993743
89778-26-7 (free base)
XFCLJVABOIYOMF-QPLCGJKRSA-N
275360-73-1
BRD-K51350053-048-06-6
NCGC00160530-13
EN300-22411559
toremifene (iarc)
2-(4-((1z)-4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-n,n-dimethylethanamine
toremifenum (latin)
dtxcid503689
(z)-4-chloro-1,2-diphenyl-1(4-(2-(n,n-dimethylamino)ethoxy)phenyl)-1-butene
l02ba02

Research Excerpts

Overview

Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. It is an effective agent for the treatment of breast cancer in postmenopausal women and is being evaluated for its ability to prevent bone fractures in men with prostate cancer taking androgen deprivation therapy.

ExcerptReferenceRelevance
"Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. "( A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
Chen, W; Chen, X; Gao, W; He, J; Hong, J; Huang, J; Huang, O; Li, Y; Shen, K; Shen, L; Wu, J; Zhu, L; Zhu, S, 2020
)
2.28
"Toremifene (TOR) is a valid and safe alternative to tamoxifen (TAM) for adjuvant endocrine therapy in breast cancer patients with a metabolic pathway that differs from that of TAM. "( Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
Cai, R; Chen, S; Fan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Wang, J; Wang, W; Xu, B; Yuan, P; Zhang, P, 2018
)
3.37
"Toremifene(TOR)is a selective estrogen receptor modulator(SERM). "( The clinical benefit of high-dose toremifene for metastatic breast cancer.
Edo, M; Higaki, M; Kitahara, K; Koike, K; Noshiro, H; Satou, S, 2013
)
2.11
"Toremifene is an anti-oestrogen agent, but possible further mechanisms of action in desmoids are related to its role in regulation of transforming growth factor-beta and β-catenin pathways."( Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis.
Baldi, GG; Barisella, M; Callegaro, D; Casali, PG; Colombo, C; Fiore, M; Gronchi, A; Morosi, C; Palassini, E; Radaelli, S; Stacchiotti, S, 2015
)
1.44
"Toremifene is a selective estrogen receptor modulator included in the list of prohibited substances in sport by the World Anti-doping Agency. "( Mass spectrometric characterization of urinary toremifene metabolites for doping control analyses.
Diaz, R; Gómez, C; Hernandez, F; Marco, MP; Pozo, OJ; Salvador, JP; Sancho, JV; Segura, J; Ventura, R; Vilaroca, E, 2011
)
2.07
"Toremifene is an effective agent for the treatment of breast cancer in postmenopausal women and is being evaluated for its ability to prevent bone fractures in men with prostate cancer taking androgen deprivation therapy. "( Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.
Dalton, JT; Johanning, KM; Kim, J; Peraire, C; Solà, J; Veverka, KA, 2011
)
2.1
"Toremifene is a triphenylethylene selective estrogen receptor modulator (SERM) that differs from tamoxifen in a single chloride ion addition on a side chain, resulting in a potentially more favorable toxicity profile."( Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis.
Gennari, L; Merlotti, D; Nuti, R; Stolakis, K, 2012
)
2.11
"Toremifene (TOR) is a selective estrogen receptor modulator used in adjuvant therapy for breast cancer and in clinical trials for prostate cancer prevention. "( Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics.
Dhakal, IB; Edavana, VK; Kadlubar, S; Williams, S; Yu, X, 2012
)
2.13
"Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile."( A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
Chen, K; Chen, L; Gu, R; Hu, Y; Jia, W; Jin, L; Li, S; Long, M; Rao, N; Song, E; Su, F; Wu, J; Wu, M; Xiao, Q; Zeng, Y, 2012
)
1.35
"Toremifene is a potent MDR modulating agent with respect to chemotherapeutic agents but has the opposite effect with respect to Tc-99m-sestamibi."( Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines.
Chaudhary, KS; Harrington, KJ; Lalani, el-N; Mubashar, M; Peters, AM; Stamp, GW, 2004
)
1.35
"Toremifene is a chlorinated derivative of tamoxifen, developed to improve its risk-benefit profile. "( Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
Castiglione-Gertsch, M; Coates, AS; Gelber, R; Gelber, S; Goldhirsch, A; Pagani, O; Price, K; Simoncini, E; Zahrieh, D, 2004
)
3.21
"Toremifene is a valid and safe alternative to tamoxifen in postmenopausal women with endocrine-responsive breast cancer."( Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
Castiglione-Gertsch, M; Coates, AS; Gelber, R; Gelber, S; Goldhirsch, A; Pagani, O; Price, K; Simoncini, E; Zahrieh, D, 2004
)
3.21
"Toremifene is an agent that predominantly has antiestrogenic properties with minimal estrogenic activities."( Toremifene, a new agent for treatment of mastalgia: an open study.
Beechey-Newman, N; Fentiman, IS; Hamed, H; Kotheri, A,
)
2.3
"Toremifene is a selective estrogen receptor modulator that exerts pharmacological activity in the breast, bone and prostate."( Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.
Barnette, G; Dalton, JT; Raghow, S; Smith, MR; Steiner, M; Taneja, SS; Veverka, KA, 2006
)
2.5
"Toremifene is a triphenylethylene antioestrogen with significant antitumor activity. "( Effect of toremifene on antipyrine elimination in the isolated perfused rat liver.
Bishop, JF; Ellis, AG; Webster, LK, 1993
)
2.13
"Toremifene (TOR) is a triphenylethylene derivative related to tamoxifen (TAM). "( Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.
Dombernowsky, P; Engelholm, SA; Herrstedt, J; Stenbygaard, LE; Svendsen, KR; Thomsen, JF, 1993
)
3.17
"Toremifene is an orally administered triphenylethylene derivative with antiestrogenic activity that is primarily used in the treatment of patients with metastatic breast cancer. "( Tissue distribution of transdermal toremifene.
Cadman, TB; DeGregorio, MW; Hubbard, GB; Mäenpää, JU; Soe, L; Theon, AP; Wiebe, VJ; Wurz, GT, 1997
)
2.02
"Toremifene (Fareston) is a triphenylethylene derivative structurally similar to tamoxifen (Nolvadex) that was selected for development based on its in vitro activity against breast cancer and its lesser uterotrophic effect than tamoxifen in rat models. "( Phase I and II studies of toremifene.
Hamm, JT, 1997
)
2.04
"Toremifene is a chlorinated tamoxifen analogue that is indicated for the treatment of postmenopausal hormone-dependent breast cancer. "( Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Ala-Fossi, SL; Mäenpää, JU, 1997
)
3.18
"Toremifene (TOR) is a new antiestrogenic agent, a triphenylethylene derivative that was developed as an alternative to tamoxifene (TAM). "( [The in vitro combination-effect of toremifene with CAF (cyclophosphamide, adriamycin, 5-fluorouracil) on growth of various human mammary carcinomas].
Abe, F; Kuroiwa, S; Maruyama, S; Okada, M, 1998
)
2.02
"Toremifene (Fareston) is an orally administered triphenylethylene derivative with chemosensitizing activity in vitro in estrogen receptor-negative multidrug-resistant human breast cancer cells. "( Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin.
Cadman, TB; DeGregorio, MW; Emshoff, VD; Soc, L; Wurz, GT, 1998
)
2.01
"Toremifene, which is a chlorinated analogue of tamoxifen, undergoes similar oxidative metabolism to give 4-hydroxytoremifene, which is further oxidized to the corresponding quinone methide."( 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides.
Bolton, JL; Fan, PW; Zhang, F, 2000
)
1.27
"Toremifene is a chlorinated triphenylethylene that is indicated for postmenopausal breast cancer. "( Toremifene. where do we stand?
Holli, K; Mäenpää, J; Pasanen, T, 2000
)
3.19
"Toremifene is a chlorinated triphenylethylene derivative of tamoxifen approved for use in the treatment of patients with metastatic breast cancer. "( Clinical pharmacokinetics of toremifene.
DeGregorio, MW; Linares, GR; Taras, TL; Wurz, GT, 2000
)
2.04
"Toremifene is a new antiestrogen, which in nonclinical studies appears less carcinogenic than tamoxifen. "( Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
Angiolini, C; Bergaglio, M; Bertelli, G; Del Mastro, L; Queirolo, P; Signorini, A; Valenzano, M; Vecchio, S; Venturini, M,
)
3.02
"Toremifene is an anti-estrogenic drug like tamoxifen. "( [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
Asaishi, K; Masuoka, H; Mori, M; Nomura, N; Sakurai, M; Shimokawara, I; Shirai, H; Usuda, N; Yoshida, K, 2002
)
2
"Toremifene is an antiestrogen that binds strongly to estrogen receptors (ER). "( Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.
Bishop, J; Fennessy, A; Leber, G; Murray, R; Olver, I; Pitt, P; Stokes, K; Webster, L, 1992
)
1.97
"Toremifene is a new antiestrogenic compound. "( Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
Gundersen, S, 1990
)
3.16
"Toremifene is a triphenylethylene derivative structurally and pharmacologically similar to tamoxifen. "( Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
DeGregorio, MW; Hamm, JT; Kohler, PC; Shemano, I; Tormey, DC; Wiebe, VJ, 1990
)
1.97
"Toremifene has proven to be an effective and well tolerated antiestrogenic compound in the treatment of locally advanced and metastatic breast cancer. "( Phase III studies of toremifene in metastatic breast cancer.
Pyrhönen, SO, 1990
)
2.04
"Toremifene is a nonsteroidal antiestrogen currently being evaluated for the treatment of breast cancer. "( Preclinical studies with toremifene as an antitumor agent.
Jordan, VC; Parker, CJ; Robinson, SP, 1990
)
2.03
"Toremifene is a new antioestrogen, developed in Finland."( The significance of estrogen receptors in tamoxifen and toremifene therapy.
Kangas, L; Valavaara, R, 1988
)
1.24

Effects

Toremifene also has a pharmacokinetic profile and metabolic pathway different from that of tamoxifen, which may provide a therapeutic advantage in certain patients. Torem ifene has a specific antiproliferative effect on KS cells.

Toremifene (TOR) has been used as an anti-oestrogen drug for the treatment and prevention of human breast cancer. It has a pharmacokinetic profile and metabolic pathway different from that of tamoxifen, which may provide a therapeutic advantage in certain patients.

ExcerptReferenceRelevance
"Toremifene also has a pharmacokinetic profile and metabolic pathway different from that of tamoxifen, which may provide a therapeutic advantage in certain patients."( Toremifene for breast cancer: a review of 20 years of data.
Braccia, D; Capers, C; Johnston, MA; Vogel, CL, 2014
)
2.57
"Toremifene has a specific antiproliferative effect on KS cells. "( Antiproliferative properties of toremifene on AIDS-related Kaposi's sarcoma cells.
Hong, A; Leigh, BR, 2002
)
2.04
"Toremifene has a dual effect on this accumulation, increasing it through an inhibitory effect on Pgp while at the same time reducing it by a direct competition with sestamibi."( 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Chaudhary, KS; Glass, DM; Harrington, KJ; Lalani, el-N; Mubashar, M; Peters, AM; Sinnett, D; Stamp, GW, 2002
)
1.3
"Toremifene also has a pharmacokinetic profile and metabolic pathway different from that of tamoxifen, which may provide a therapeutic advantage in certain patients."( Toremifene for breast cancer: a review of 20 years of data.
Braccia, D; Capers, C; Johnston, MA; Vogel, CL, 2014
)
2.57
"Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. "( Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
Eshima, N; Kasumi, F; Kimijima, I; Kimura, M; Masuda, N; Noguchi, S; Nomura, Y; Takashima, S; Takatsuka, Y; Tominaga, T; Yamaguchi, A, 2010
)
2.19
"Toremifene (TOR) has been used as an anti-oestrogen drug for the treatment and prevention of human breast cancer. "( Synthesis, radiolabeling and In Vivo tissue distribution of an anti-oestrogen glucuronide compound, (99m)Tc-TOR-G.
Enginar, H; Ichedef, C; Kilcar, AY; Muftuler, FZ; Sakarya, S; Unak, P; Yolcular, S, 2010
)
1.8
"Toremifene has a specific antiproliferative effect on KS cells. "( Antiproliferative properties of toremifene on AIDS-related Kaposi's sarcoma cells.
Hong, A; Leigh, BR, 2002
)
2.04
"Toremifene has been in clinical use for 8 years for the treatment of advanced hormone-sensitive breast cancer and the adjuvant treatment of early breast cancer. "( Toremifene: an evaluation of its safety profile.
Hajba, A; Harvey, HA; Kimura, M, 2006
)
3.22
"Toremifene has no effect on the NO-ET-1 ratio."( The cardiovascular effects of selective estrogen receptor modulators.
Botsis, DC; Christodoulakos, GE; Lambrinoudaki, IV, 2006
)
1.06
"Toremifene has yielded some positive findings for genotoxicity, but was not an initiating carcinogen in experimental animals."( Safety assessment of tamoxifen and toremifene.
Jeffrey, AM; Williams, GM, 1997
)
1.3
"Toremifene has favourable effects on serum lipids, and thus has potential in preventing coronary heart disease."( Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Ala-Fossi, SL; Mäenpää, JU, 1997
)
2.46
"Toremifene has antiestrogenic and estrogenic properties in vitro and in vivo. "( Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial.
Armstead, B; Haller, D; Holroyde, C; Malkowicz, SB; Peacock, T; Stein, S; Vaughn, DJ; Zoltick, B, 2001
)
2.09
"Toremifene has also shown to be genotoxic, but to a far lower extent, by inducing micronuclei in MCL-5 a cells in vitro and by inducing aneuploidy in rat liver in vivo."( Toxicity of antiestrogens.
Aaltonen, A; Hirsimäki, P; Mäntylä, E,
)
0.85
"Toremifene has a dual effect on this accumulation, increasing it through an inhibitory effect on Pgp while at the same time reducing it by a direct competition with sestamibi."( 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Chaudhary, KS; Glass, DM; Harrington, KJ; Lalani, el-N; Mubashar, M; Peters, AM; Sinnett, D; Stamp, GW, 2002
)
1.3
"Toremifene has definite antitumor effect in advanced breast cancer."( Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
Gundersen, S, 1990
)
2.44
"Toremifene has proven to be an effective and well tolerated antiestrogenic compound in the treatment of locally advanced and metastatic breast cancer. "( Phase III studies of toremifene in metastatic breast cancer.
Pyrhönen, SO, 1990
)
2.04

Actions

Toremifene failed to increase BMD at any site measured. A slight trend toward a fall (-0.3 to -0.9%) in BMD was seen in patients treated with toremifene. Toremifenes and tamoxifen produce identical effects in our endometrial cancer models.

ExcerptReferenceRelevance
"Toremifene showed lower binding in each system, and in lymhocytes adducts were only detected at a cytotoxic dose level."( DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro.
Hemminki, K; Hou, SM; Widlak, P, 1995
)
1.29
"Toremifene failed to increase BMD at any site measured, and in contrast, a slight trend toward a fall (-0.3 to -0.9%) in BMD was seen in patients treated with toremifene."( Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
Hietanen, P; Marttunen, MB; Tiitinen, A; Ylikorkala, O, 1998
)
1.29
"Toremifene and tamoxifen produce identical effects in our endometrial cancer models. "( Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
Assikis, VJ; Bilimoria, MM; Chatterton, R; Cisneros, A; Dragan, YP; England, GM; Jordan, VC; MacGregor, JI; Muenzner, HD; O'Regan, RM; Piette, M; Pitot, HC, 1998
)
2.01

Treatment

Treatment with toremifene (all doses) or tamoxifen (1 and 10 mg/kg) for 28 days produced a decrease in overall uterine size and myometrial thickness. However, uterine luminal and glandular epithelia cell height increased (P<0.05) compared with control.

ExcerptReferenceRelevance
"Toremifene treatment reduced GAG and collagen synthesis, TGFbeta1 activity and fibronectin levels in all cell cultures."( Toremifene decreases type I, type II and increases type III receptors in desmoid and fibroma and inhibits TGFbeta1 binding in desmoid fibroblasts.
Balducci, C; Becchetti, E; Calastrini, C; Carinci, F; Dolci, C; Lilli, C; Locci, P; Lumare, E; Marinucci, L; Stabellini, G, 2008
)
2.51
"In toremifene-treated tumors, A/V INDEX was strongly correlated with TRPM-2-gene expression, which was also enhanced when compared with the controls."( Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene.
Collan, Y; Huovinen, R; Wärri, A, 1993
)
1.01
"Toremifene citrate treated silica xerogel implants were tested both in vitro and in vivo using healthy mice."( Silica xerogel as an implantable carrier for controlled drug delivery--evaluation of drug distribution and tissue effects after implantation.
Ahola, M; Kangasniemi, I; Karlsson, S; Kiesvaara, J; Kortesuo, P; Yli-Urpo, A, 2000
)
1.03
"Toremifene treatment did not affect steatosis, but significantly reduced inflammation and necrosis."( The antiestrogen toremifene protects against alcoholic liver injury in female rats.
Heinaro, S; Järveläinen, HA; Lindros, KO; Lukkari, TA; Sippel, H, 2001
)
1.37
"Toremifene treatment did not affect androgen receptor levels."( Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
Hooshdaran, MZ; Katiyar, S; Raghow, S; Steiner, MS, 2002
)
2.48
"Treatment with toremifene and interferon alfa-2b was successful and well tolerated in our two patients. "( Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases.
Binion, DG; Heidemann, J; Ogawa, H; Otterson, MF; Shidham, VB, 2004
)
0.92
"Treatment with toremifene 20 mg/day and leuprolide resulted in a dramatic improvement of the performance status and complete remission of all the abdominal lesions."( Ovarian luteinized thecoma with sclerosing peritonitis in an adult woman treated with leuprolide and toremifene in complete remission at 5 years.
Bianco, AR; Bianco, R; de Rosa, G; Somma, P; Staibano, S, 2005
)
0.88
"Treatment with toremifene (all doses) or tamoxifen (1 and 10 mg/kg) for 28 days produced a decrease (P<0.05) in overall uterine size and myometrial thickness; however, uterine luminal and glandular epithelia cell height increased (P<0.05) compared with control."( Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat.
Grubbs, CJ; Khan, SA; Lubet, RA; Nephew, KP; Osborne, E, 2000
)
0.91

Toxicity

The side-effect profile of toremifene resembles that of tamoxifen. Most of the adverse effects are related to its activity at estrogen receptors and include hot flashes, vaginal discharge and nausea.

ExcerptReferenceRelevance
" Adverse effects were experienced in 3 (5."( [Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer].
Abe, O; Asaishi, K; Izuo, M; Nomura, Y; Tominaga, T, 1993
)
0.55
" Most of the adverse effects of toremifene are related to its activity at estrogen receptors and include hot flashes, vaginal discharge and nausea."( Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Ala-Fossi, SL; Mäenpää, JU, 1997
)
2.02
" The subjective side-effect profile was similar in both treatment groups."( Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Blanco, G; Flander, M; Hietanen, P; Holli, K; Joensuu, H; Kataja, V; Pukkala, E; Valavaara, R, 2000
)
0.54
"The side-effect profile of toremifene resembles that of tamoxifen."( Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Blanco, G; Flander, M; Hietanen, P; Holli, K; Joensuu, H; Kataja, V; Pukkala, E; Valavaara, R, 2000
)
0.84
" Serum protected the cells from the toxic effects of the drugs."( Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells.
Diehl, H; Engelke, M; Huhtala, A; Mäenpää, H; Mannerström, M; Mäntylä, E; Mäntylä, M; Marselos, M; Pappas, P; Salminen, L; Tähti, H; Toimela, T; Uusitalo, H; Zorn-Kruppa, M, 2002
)
0.31
" There were 3 mild adverse events, and no serious adverse events."( Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia.
Pound, CR; Steiner, MS, 2003
)
0.56
"Ocular toxicity during adjuvant therapy is a common side effect mainly represented by irritative symptoms due to chemotherapy."( Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Gelber, RD; Gianni, L; Goldhirsch, A; Holmberg, SB; Li, S; Panzini, I; Ravaioli, A, 2006
)
0.33
" The severities of adverse effects were all less than grade 2; the major ones were flushing and sweating."( [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
Abe, N; Ishigame, T; Ishii, M; Ito, J; Ito, T; Kimijima, I; Miyamoto, K; Ohtake, T; Takenoshita, S; Watanabe, K; Yasuda, M; Yoshida, S, 2009
)
0.63
" This meta-analysis suggested that toremifene was as effective as tamoxifen in the adjuvant setting for both perimenopausal and postmenopausal breast cancer patients with similar severe adverse effects to tamoxifen."( Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.
Chen, L; Ding, Q; Liu, XA; Wang, S; Zhou, WB, 2011
)
2.09
"Toremifene may be a valid and safe alternative to tamoxifen in premenopausal women with endocrine-responsive breast cancer."( A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
Chen, K; Chen, L; Gu, R; Hu, Y; Jia, W; Jin, L; Li, S; Long, M; Rao, N; Song, E; Su, F; Wu, J; Wu, M; Xiao, Q; Zeng, Y, 2012
)
2.07
" Lipid metabolism disorder was the most common adverse event (69."( Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.
Guan, X; Li, C; Li, H; Li, L; Liu, B; Ma, F; Qian, H; Rong, G; Sun, X; Wang, W; Xu, B; Yi, Z; Zhai, J, 2020
)
0.56

Pharmacokinetics

The half-life of toremifene is approximately 5 days, and steady state is reached by 6 weeks depending on the dose given. In normal subjects, the average peak level of 414 ng/ml was achieved at 3 hours after dosing.

ExcerptReferenceRelevance
"A multicenter phase I pharmacokinetic study of a new triphenylethylene antiestrogen, toremifene, was examined in 70 patients with advanced breast cancer."( Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer.
Benz, CC; Cadman, TB; DeGregorio, MW; Shemano, I; Wiebe, VJ, 1990
)
0.83
" The half-life was found to be 5 days, and at three weeks following discontinuation of treatment concentrations greater than 24 ng/ml were detected."( Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
DeGregorio, MW; Hamm, JT; Kohler, PC; Shemano, I; Tormey, DC; Wiebe, VJ, 1990
)
0.53
" Serum levels of toremifene and its metabolites were determined; appropriate pharmacokinetic parameters were calculated and statistically evaluated."( Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function.
Anttila, M; Laakso, S; Nyländen, P; Sotaniemi, EA, 1995
)
0.88
" Serum levels of the parent drug and the metabolites were determined; appropriate pharmacokinetic parameters were calculated and statistically evaluated."( Influence of age on toremifene pharmacokinetics.
Anttila, MI; Sotaniemi, EA, 1997
)
0.62
" Following doxorubicin administration in each cycle, blood specimens were collected over a 72-h period for determination of the terminal half-life of elimination."( Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin.
Cadman, TB; DeGregorio, MW; Emshoff, VD; Soc, L; Wurz, GT, 1998
)
0.57
"Prior to toremifene dosing, baseline doxorubicin pharmacokinetic studies showed an average terminal half-life of elimination of 40."( Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin.
Cadman, TB; DeGregorio, MW; Emshoff, VD; Soc, L; Wurz, GT, 1998
)
0.99
" The half-life of toremifene is approximately 5 days, and steady state is reached by 6 weeks depending on the dose given."( Clinical pharmacokinetics of toremifene.
DeGregorio, MW; Linares, GR; Taras, TL; Wurz, GT, 2000
)
0.93
" Some P-gp moderators may change the pharmacokinetic parameters of PXL in vivo."( Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
Aogi, K; Kakishita, T; Nishikawa, K; Ohama, Y; Okita, A; Okita, R; Saeki, T; Taira, N; Takashima, S, 2009
)
0.58
" For the pharmacokinetic study, PXL was administered on days 1, 8, 15, 32, and 39; TOR was given from day 18 to the end of study."( Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
Aogi, K; Kakishita, T; Nishikawa, K; Ohama, Y; Okita, A; Okita, R; Saeki, T; Taira, N; Takashima, S, 2009
)
0.58
" The overall pharmacokinetic profile is remarkably similar to tamoxifen."( Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis.
Gennari, L; Merlotti, D; Nuti, R; Stolakis, K, 2012
)
0.66

Compound-Compound Interactions

Low-dose weekly paclitaxel (60 mg/body/week) combined with toremifene (120 mg/day) was started in December 1999.

ExcerptReferenceRelevance
" Low-dose weekly paclitaxel (60 mg/body/week) combined with toremifene (120 mg/day) was started in December 1999."( [A case of breast cancer with bone marrow and liver metastases responding completely to low-dose weekly paclitaxel combined with toremifene].
Kameda, K; Kubo, A; Mochizuki, Y; Momiyama, N; Natori, S; Takekawa, Y, 2001
)
0.76
" Due to the potential for drug-drug interactions, the ability of toremifene and its primary circulating metabolite N-desmethyltoremifene (NDMT) to inhibit nine human cytochrome P450 (CYP) enzymes was determined using human liver microsomes."( Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.
Dalton, JT; Johanning, KM; Kim, J; Peraire, C; Solà, J; Veverka, KA, 2011
)
0.9
"The present study was designed to provide preliminary information on the potential impact of metabolic drug-drug interaction on the effectiveness of doping control strategies currently followed by the anti-doping laboratories to detect the intake of banned agents."( Drug-drug interaction and doping, part 1: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene.
Botrè, F; de la Torre, X; Fiacco, I; Mazzarino, M; Palermo, A, 2014
)
0.61
"To explore the efficacy and safety of everolimus combined with endocrine therapy in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER-2)-negative advanced breast cancer."( Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negativeadvanced breast cancer.
Chen, C; Kong, F; Lu, J; Shan, H; Song, X; Wang, L; Yuan, H,
)
0.13
" Of them, 54 patients were treated with everolimus combined with endocrine drugs (Everolimus group), while the other 54 patients underwent endocrine monotherapy (Control group)."( Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negativeadvanced breast cancer.
Chen, C; Kong, F; Lu, J; Shan, H; Song, X; Wang, L; Yuan, H,
)
0.13
"Everolimus combined with endocrine therapy has significant clinical efficacy in patients with HR-positive/HER-2-negative advanced breast cancer, and can effectively improve the survival of patients with tolerable adverse reactions."( Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negativeadvanced breast cancer.
Chen, C; Kong, F; Lu, J; Shan, H; Song, X; Wang, L; Yuan, H,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" Oral bioavailability is estimated to be approximately 100%."( Clinical pharmacokinetics of toremifene.
DeGregorio, MW; Linares, GR; Taras, TL; Wurz, GT, 2000
)
0.6

Dosage Studied

The cytotoxicity of the selected systemic and intravitreally dosed drugs tamoxifen, toremifene, chloroquine, 5-fluorouracil, gentamicin and ganciclovir was studied in r.

ExcerptRelevanceReference
" Patients received a single oral dosing or daily once oral dosing for five consecutive days."( [Phase I study of NK 622 (toremifene citrate)].
Abe, O; Abe, R; Asaishi, K; Hayasaka, A; Hayashi, K; Iino, Y; Izuo, M; Kimishima, I; Tominaga, T; Yokoe, T, 1992
)
0.58
" Our results show that a dose-response relationship exists between cell growth inhibition and cell cycle measurements for human plasma with added toremifene or tamoxifen, and also for human plasma specimens containing drug and its metabolites after treatment."( A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.
DeGregorio, M; Emshoff, V; Koester, S; Minor, P; Wiebe, V; Wurz, G, 1992
)
0.48
" One hundred and seven women were treated at one of six dosage levels (10, 20, 40, 60, 200, or 400 mg/d orally) for at least 8 weeks."( Phase I study of toremifene in patients with advanced cancer.
Green, M; Haller, D; Hamm, JT; Kohler, PC; Shemano, I; Tormey, DC, 1991
)
0.62
" We detected no clear evidence of a dose-response effect for TOR."( Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
Berris, RF; Bezwoda, WR; Goedhals, L; Hacking, A; Hayes, DF; Jones, SE; Mailliard, JA; Shemano, I; Van Zyl, JA; Vogel, CL, 1995
)
0.53
" The major adducts formed following incubation of DNA with tamoxifen had similar Rf values to two of the 32P-postlabelled adducts seen following dosing of rats with tamoxifen."( Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts.
Davies, AM; Jones, RM; Lim, CK; Martin, EA; Smith, LL; White, IN, 1995
)
0.56
" Female Sprague-Dawley rats were dosed with equimolar doses of tamoxifen (11."( Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat.
Ahotupa, M; Hirsimäki, P; Mäntylä, E; Pärssinen, R, 1994
)
0.29
"In this nonblinded, controlled multicenter trial, postmenopausal women were randomly assigned to receive graded doses of toremifene and tamoxifen or no antiestrogen to assess dose-response levels and evaluation methodology."( Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women.
Bump, RC; Gams, RA; Harry, DS; Hickox, PG; Homesley, HD; Mullin, TJ; O'Toole, RV; Rebar, RW; Shemano, I; Wentz, AC, 1993
)
0.79
" No tumor was observed in the toremifene-treated rats (48 mg/kg per day) either after 52 weeks of dosing or after the recovery period."( Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens.
Hirsimäki, P; Hirsimäki, Y; Nieminen, L; Payne, BJ, 1993
)
0.57
", approximately 35% [CR+PR] in unselected patients), although dosage regimens of the new antiestrogens are higher than the 20 mg tamoxifen required daily."( Alternate antiestrogens and approaches to the prevention of breast cancer.
Jordan, VC, 1995
)
0.29
" Liver DNA from animals dosed with tamoxifen at 10 mg/kg also showed a similar increase in MF."( Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats.
Davies, R; Festing, MF; Martin, EA; Oreffo, VI; Smith, LL; Styles, JA; White, IN, 1997
)
0.3
" Based on this dose-response analysis, a 10-microg dose of toremifene was chosen to assess uterine development after neonatal exposure (PND 1-5)."( Effects of toremifene on neonatal rat uterine growth and differentiation.
Branham, WS; Medlock, KL; Sheehan, DM, 1997
)
0.93
" It is concluded that the dosage requirement of the drug is unlikely to differ between young and elderly subjects."( Influence of age on toremifene pharmacokinetics.
Anttila, MI; Sotaniemi, EA, 1997
)
0.62
" During toremifene pre-treatment, blood specimens (5 ml) were drawn at 0, 2, 4, and 24 h after dosing to assess peak levels."( Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin.
Cadman, TB; DeGregorio, MW; Emshoff, VD; Soc, L; Wurz, GT, 1998
)
1.01
" I33' may have accounted for Vg increases observed in trout fed I3C as it is present in liver after oral dosing at concentrations (70 microM) expected to maximally induce Vg."( 3,3'-diindolylmethane, a major condensation product of indole-3-carbinol, is a potent estrogen in the rainbow trout.
Carlson, DB; Katchamart, S; Shilling, AD; Williams, DE, 2001
)
0.31
" Tamoxifen induced increased cell cycle activity in the livers of rats following gavage dosing at all sampling times (1-12 weeks), whereas toremifene had no effect on the incidence of cycling in hepatic cells, demonstrating that the hepatic cell proliferation is not a general response to anti-oestrogen treatment."( Delayed effects of tamoxifen in hepatocarcinogenesis-resistant Fischer 344 rats as compared with susceptible strains.
Carthew, P; Davies, R; Higginson, F; Martin, E; Stanley, LA; Styles, JA, 2001
)
0.51
" Uterine adenomyosis was found in all (14 of 14) mice dosed with tamoxifen and most mice (12 of 14) treated with toremifene, but in none of the vehicle-dosed controls, in only one animal treated with raloxifene at 42 and 90 days after dosing and in none of the mice treated with estradiol at 42 days."( Adenomyosis--a result of disordered stromal differentiation.
Butterworth, M; Greaves, P; Green, A; Parrott, E; White, IN, 2001
)
0.52
"The cytotoxicity of the selected systemic and intravitreally dosed drugs tamoxifen, toremifene, chloroquine, 5-fluorouracil, gentamicin and ganciclovir was studied in retinal pigment epithelium (RPE) in vitro."( Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells.
Diehl, H; Engelke, M; Huhtala, A; Mäenpää, H; Mannerström, M; Mäntylä, E; Mäntylä, M; Marselos, M; Pappas, P; Salminen, L; Tähti, H; Toimela, T; Uusitalo, H; Zorn-Kruppa, M, 2002
)
0.54
" The compounds were dosed (s."( Histopathology and histomorphometry of the urogenital tract in 15-month old male and female rats treated neonatally with SERMs and estrogens.
Karlsson, S, 2006
)
0.33
" In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules."( [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007
)
0.54
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" The plasma concentrations of TOR and its N-desmethyl (NDM) and 4-hydroxy (4-OH) metabolites during steady-state dosing with TOR were also determined."( Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.
Barrett, CM; Bohl, CE; Coss, CC; Dalton, JT; He, Y; Kim, J; Li, CM; Mohler, ML; Veverka, KA, 2013
)
0.61
" Using an in vitro model of Ebola Zaire replication with transcription-competent virus like particles (trVLPs), requiring only level 2 biosafety containment, we compared the activities of the type I interferons (IFNs) IFN-α and IFN-ß, a panel of viral polymerase inhibitors (lamivudine (3TC), zidovudine (AZT) tenofovir (TFV), favipiravir (FPV), the active metabolite of brincidofovir, cidofovir (CDF)), and the estrogen receptor modulator, toremifene (TOR), in inhibiting viral replication in dose-response and time course studies."( A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus.
Baker, DP; Branch, DR; Fish, EN; Hoenen, T; Kobinger, GP; Kozlowski, HN; Majchrzak-Kita, B; McCarthy, SD; Racine, T, 2016
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
estrogen antagonistA compound which inhibits or antagonises the biosynthesis or actions of estrogens.
estrogen receptor modulatorA substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure.
bone density conservation agentAn agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
PPM1D proteinHomo sapiens (human)Potency18.55690.00529.466132.9993AID1347411
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
gemininHomo sapiens (human)Potency33.49830.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency19.95260.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency18.55690.00339.158239.8107AID1347411
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)3.58000.00022.45859.9600AID1804171
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki4.12500.00020.522910.0000AID691260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)12.43500.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)12.43500.00304.57559.8200AID1804127
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)12.43500.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)12.43500.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)12.43500.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)12.43500.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)12.43500.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)12.43500.00304.11059.8200AID1804127
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)12.43500.00304.57559.8200AID1804127
Envelope glycoproteinEbola virus - Mayinga, Zaire, 1976EC50 (µMol)0.06280.06280.06280.0628AID1660617; AID1660618
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)12.43500.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (82)

Processvia Protein(s)Taxonomy
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (107)

Assay IDTitleYearJournalArticle
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1676116Binding affinity to glycoprotein L184M mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1676105Antiviral activity against Mengla-virus assessed as inhibition of viral entry2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1472913Binding affinity to Ebola virus Zaire Mayinga-76 recombinant GP protein assessed as change in melting temperature at 500 uM by SYPRO orange dye-based fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID1676120Selectivity index, ratio of CC50 for human A549 cells to IC50 for antiviral activity against pseudotyped Marburgvirus-Angola infected in human A549 cells2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1863557Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by cellular ATP method2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1660611Selectivity index, ratio of CC50 for human A549 cells to EC50 for HIV/EBOV-GP infected in human A549 cells2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
AID1283250Inhibition of delta 8-7 isomerase in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in cholesterol levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID411793Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1863560Inhibition of glycoprotein in luciferase expressing pseudotyped VSV infected in human Huh-7 cells assessed as inhibition of viral entry by measuring inhibition of virus-expressed reporter bioluminescence pretreated with cells for 30 mins followed by incub2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1283275Inhibition of DR24 in mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1847245Antiviral activity against Ebola virus2021European journal of medicinal chemistry, Nov-05, Volume: 223Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
AID1863562Antiviral activity against pseudotyped Ebola virus assessed as inhibition of viral entry2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1660612Selectivity index, ratio of CC50 for human A549 cells to EC50 for HIV/MARV-GP infected in human A549 cells2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
AID1283267Cytotoxicity against human SLOS fibroblasts at 5 uM after 5 days by Cell Titer assay2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1472910Binding affinity to Ebola virus Zaire Mayinga-76 recombinant GP protein by SYPRO orange dye-based fluorescence assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID1283263Inhibition of DR24 in human SLOS fibroblasts assessed as decrease in 7-DHC levels at 100 nM after 5 days by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1661954Binding affinity to Ebola virus glycoprotein assessed as dissociation constant incubated for 20 to 30 mins by microscale thermophoresis2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.
AID1676122Selectivity index, ratio of CC50 for human A549 cells to IC50 for antiviral activity against pseudotyped Ebola virus - Zaire (1995) Kikwit infected in human A549 cells2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1661955Binding affinity to Ebola virus glycoprotein2020ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8
Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.
AID1283248Inhibition of delta 8-7 isomerase in Dhcr7-deficient mouse Neuro2a cells assessed as increase in zymostenol levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1545817Antiproliferative activity against human MCF7 cells by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1863556Inhibition of glycoprotein in luciferase expressing pseudotyped Ebola virus infected in human Huh-7 cells assessed as inhibition of viral entry by measuring inhibition of virus-expressed reporter bioluminescence pretreated with cells for 30 mins followed 2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1283268Inhibition of delta 8-7 isomerase in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1533451Antiviral activity against Ebolavirus2019European journal of medicinal chemistry, Jan-15, Volume: 162Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1676123Antiviral activity against pseudotyped Ebola virus - Zaire (1995) Kikwit infected in human A549 cells assessed as reduction in viral infection incubated for 24 hrs by Hoechst staining based fluorescence assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1602789Antiviral activity against HIV-1-derived Ebolavirus pseudoparticle infected in human TZM-bl cells after 48 hrs by beta-gal based reporter assay2019Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library.
AID681359TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells1994Biochemical pharmacology, Jul-19, Volume: 48, Issue:2
Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.
AID1375643Antiviral activity against Ebolavirus like particle harboring full length EBOV Zaire wt/GIN/2014/ Kissidougou-C15 envelope glycoprotein and Influenzae virus envelope assessed as inhibition of viral infection in MDCK-SIAT1 cells after 48 hrs by e-GFP-based2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1676124Selectivity index, ratio of CC50 for human A549 cells to IC50 for antiviral activity against pseudotyped Marburgvirus-Musoke infected in human A549 cells2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1660613Antiviral activity against Ebola virus 1976 Mayinga infected in human HeLa cells pretreated for 1 hr followed by virus infection measured after 24 hrs by Hoechst staining-based immunofluorescence assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
AID1676115Binding affinity to glycoprotein L515V mutant in pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells at 0.12 to 250 uM assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay relative to wild type2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1472912Antiviral activity against Ebolavirus infected in human HepG2 cells assessed as reduction in virus entry after 48 hrs by Celltiter-Glo luminescent assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1660617Inhibition of HIV/EBOV GP Y517S mutant infected in 293T cells assessed as reduction in virus entry2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
AID1863561Specificity index, ratio of IC50 for inhibition of glycoprotein in luciferase expressing pseudotyped VSV infected in human Huh-7 cells to IC50 for inhibition of glycoprotein in luciferase expressing pseudotyped Ebola virus infected in human Huh-7 cells2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1375642Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain T42A mutant tagged with 6xHis/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells at pH 5.2 by SYPRO orange dye-2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1660618Inhibition of HIV/EBOV GP T519V mutant infected in 293T cells assessed as reduction in virus entry2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
AID1676104Antiviral activity against Ebolavirus (pBDBV) assessed as inhibition of viral entry2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1375644Antiviral activity against Ebolavirus expressing eGFP infected in African green monkey Vero E6 cells assessed as inhibition of viral replication after 48 hrs by spectrofluorometric method2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1545861Cytotoxicity against human MCF10A cells by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1676125Selectivity index, ratio of CC50 for human A549 cells to IC50 for antiviral activity against pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1676106Antiviral activity against Ebolavirus Tai Forest assessed as inhibition of viral entry2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1533454Antiviral activity against Ebolavirus infected in mouse assessed as protection against viral infection at 60 mg/kg/day relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action.
AID1375639Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain T42A mutant tagged with 6xHis/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells assessed as decrease in meltin2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1676126Antiviral activity against pseudotyped Ebola virus - Mayinga, Zaire infected in human A549 cells assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1283247Inhibition of delta 8-7 isomerase in mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1676107Antiviral activity against Ebolavirus (pRESTV) assessed as inhibition of viral entry2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1676121Antiviral activity against pseudotyped Marburgvirus-Angola infected in human A549 cells assessed as reduction in viral infection incubated for 24 hrs by Hoechst staining based fluorescence assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1660607Inhibition of pseudotyped HIV/EBOV GP infected in human A549 cells assessed as reduction in virus entry measured after 48 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
AID1283274Inhibition of delta 8-7 isomerase in human SLOS fibroblasts assessed as decrease in 7-DHC levels at 100 nM after 5 days by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID691260Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells after 1.5 hrs by liquid scintillation counting2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.
AID1863558Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for inhibition of glycoprotein in luciferase expressing pseudotyped Ebola virus infected in human Huh-7 cells2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1545836Antiproliferative activity against human MDA-MB-231 cells by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 1831,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID503305Antiproliferative activity against human PC3 cells at 500 nM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1472911Antiviral activity against Ebolavirus infected in african green monkey Vero E6 cells assessed as reduction in virus entry after 48 hrs by by Celltiter-Glo luminescent assay2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.
AID1375645Antiviral activity against Ebolavirus like particle harboring EBOV VP40 assessed as inhibition of viral infection in human HeLa cells preincubated with host cells for 1 hrs followed by viral inoculation by beta-lactamse reporter assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1660616Selectivity index, ratio of CC50 for human HeLa cells to EC50 for Ebola virus 1976 Mayinga in human HeLa cells2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
AID1283269Inhibition of DR24 in Dhcr7-deficient mouse Neuro2a cells assessed as decrease in 7-DHC levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1660615Antiviral activity against Marburg virus Lake Victoria, 2005 Angola infected in human HeLa cells pretreated for 1 hr followed by virus infection measured after 24 hrs by Hoechst staining-based immunofluorescence assay2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.
AID1676127Antiviral activity against pseudotyped Marburgvirus-Musoke infected in human A549 cells assessed as reduction in viral infection incubated for 48 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
AID1283249Inhibition of delta 8-7 isomerase in Dhcr7-deficient mouse Neuro2a cells assessed as increase in zymosterol levels at 1 uM by LC-MS/GC-MS analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (563)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (3.73)18.7374
1990's205 (36.41)18.2507
2000's189 (33.57)29.6817
2010's124 (22.02)24.3611
2020's24 (4.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.87 (24.57)
Research Supply Index6.57 (2.92)
Research Growth Index5.47 (4.65)
Search Engine Demand Index112.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials109 (18.11%)5.53%
Reviews74 (12.29%)6.00%
Case Studies50 (8.31%)4.05%
Observational2 (0.33%)0.25%
Other367 (60.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture [NCT03925233]300 participants (Anticipated)Observational2019-01-02Enrolling by invitation
[NCT02132000]Phase 2/Phase 33,036 participants (Anticipated)Interventional2014-04-30Recruiting
Study of Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea [NCT02132390]Phase 3300 participants (Anticipated)Interventional2014-05-31Not yet recruiting
Multicenter Prospective, Parallel-controlled Phase III Clinical Study on Comparing Efficacy of Tamoxifen Versus Toremifene in CYP2D6 Intermediate/Poor Metabolizers of Premenopausal Patients With ER-positive Early Breast Cancer [NCT03351062]Phase 3844 participants (Anticipated)Interventional2017-11-30Recruiting
Phase II Multicenter Randomized Study to Compare Neoadjuvant Toremifene With Melatonin or Metformin Versus Toremifene in the Therapy of Locally Advanced Breast [NCT02506790]Phase 296 participants (Anticipated)Interventional2015-07-31Recruiting
Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer: A Randomized, Controlled, Prospective, Observational Study [NCT02344940]Phase 4104 participants (Actual)Interventional2014-12-31Completed
Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients [NCT02089854]Phase 4800 participants (Anticipated)Interventional2014-11-30Recruiting
Prognostic Evaluation of Changing Endocrine Therapy in Perimenopausal and Recently Postmenopausal Women With Early-stage Hormone Receptor-Positive Breast Cancer [NCT02097459]Phase 3600 participants (Anticipated)Interventional2014-03-31Recruiting
Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy [NCT01214291]Phase 30 participants (Actual)Interventional2011-03-31Withdrawn(stopped due to cost of conducting the study and increased burden on the clinical trial professionals make it impossible for us to proceed with the development of the drug.)
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study [NCT05801705]700 participants (Anticipated)Observational2023-06-01Not yet recruiting
Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) [NCT05472792]Phase 290 participants (Anticipated)Interventional2022-05-17Recruiting
[NCT00044291]Phase 3865 participants (Actual)Interventional2002-06-30Completed
Selective Estrogen Modulation and Melatonin in Early COVID-19 [NCT04531748]Phase 20 participants (Actual)Interventional2021-12-31Withdrawn(stopped due to Funding)
Pilot Study of Estradiol-Receptor Blockade in Older Men and Women [NCT02271282]Phase 140 participants (Actual)Interventional2014-12-31Completed
Volume and Circulation Changes of The Breast in 3D Ultrasound During Toremifene Versus Nonmedicated Menstrual Cycle [NCT01417754]Phase 320 participants (Actual)Interventional2010-09-30Completed
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging Findings in Women Suffering From Premenstrual Mastalgia [NCT00534846]Phase 310 participants (Actual)Interventional2007-04-30Completed
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With Hormone Receptor-positive Intraductal Carcinoma of the Breast: A Multicenter, Retrospective, Real-world Study [NCT04666805]1,354 participants (Anticipated)Observational2020-07-01Active, not recruiting
Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [NCT00097344]Phase 3842 participants Interventional2004-12-31Terminated(stopped due to Identical study Biomed 777-CLP-029 did not meet superiority endpoint)
Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer [NCT00267553]Phase 3200 participants Interventional2005-11-30Terminated(stopped due to This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint)
Antiestrogen vs Aromatase Inhibitor After Chemotherapy for Adjuvant Setting: Efficacy of Endocrine Therapy After Chemotherapy in Postoperative Adjuvant Therapy for Breast Cancer [NCT00437359]Phase 2240 participants (Anticipated)Interventional2007-05-31Terminated
A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy [NCT00129142]Phase 31,200 participants Interventional2003-10-31Completed
Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary [NCT00003865]Phase 20 participants (Actual)Interventional1999-07-22Withdrawn
Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer [NCT00010322]Phase 30 participants Interventional2000-10-31Terminated(stopped due to Withdrawn due to change in standard of care - new protocol required)
[NCT00028353]Phase 2500 participants Interventional2001-04-30Completed
A Phase II Randomized Controlled Clinical Trial Of The Antiestrogen GTx-006 In Subjects With Prostate Cancer [NCT00020735]Phase 245 participants (Actual)Interventional2001-04-30Completed
Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone. [NCT00002529]Phase 3452 participants (Actual)Interventional1993-05-31Completed
PHASE II STUDY OF THE SAFETY AND EFFICACY OF TOREMIFENE IN THE THERAPY OF DESMOID TUMORS [NCT00002595]Phase 272 participants (Anticipated)Interventional1991-07-31Completed
An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR) [NCT03238703]Phase 40 participants (Actual)Interventional2018-09-01Withdrawn(stopped due to Administrative closure based on sponsor recommendation, prior to subject enrollment)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) [NCT00106691]Phase 31,589 participants (Actual)Interventional2005-01-31Completed
Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets [NCT02353429]Phase 225 participants (Anticipated)Interventional2012-11-30Recruiting
A Prospective, Randomized, Open-label Phase III Clinical Study of the Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy Versus Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer [NCT05891093]Phase 3766 participants (Anticipated)Interventional2023-06-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00106691 (8) [back to overview]Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)
NCT00106691 (8) [back to overview]Occurrence of a Positive Cancer Biopsy
NCT00106691 (8) [back to overview]The Effect of Toremifene on % Free Serum PSA (Prostate Specific Antigen) Levels, Change From Baseline
NCT00106691 (8) [back to overview]The Effect of Toremifene on the Mean Change at 36 Months in AUA (American Urological Association) Symptom Score
NCT00106691 (8) [back to overview]The Effect of Toremifene on Total PSA (Prostate Specific Antigen) Levels
NCT00106691 (8) [back to overview]Occurrence of High Grade PIN at the 12, 24, 36 Month Biopsies
NCT00106691 (8) [back to overview]The Effect of Toremifene on Hormone Levels
NCT00106691 (8) [back to overview]The Effect of Toremifene on Lipid Levels

Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)

To measure the efficacy of toremifene citrate in men with high grade prostatic intraepithelial neoplasia (PIN). Prostate cancer-free survival distributions (Kaplan-Meier) (NCT00106691)
Timeframe: The outcome measurement time is up to 36 months

Intervention% of participants cancer-free 36 months (Number)
Placebo54.9
Toremifene 20mg59.5

[back to top]

Occurrence of a Positive Cancer Biopsy

To measure the occurrence of a positive cancer biopsy (NCT00106691)
Timeframe: Up to 36 months

InterventionMonths (Median)
Placebo23.5
20 mg. Toremifene15.9

[back to top]

The Effect of Toremifene on % Free Serum PSA (Prostate Specific Antigen) Levels, Change From Baseline

To assess the effect of toremifene in % free serum PSA (prostate specific antigen) levels, change from baseline (NCT00106691)
Timeframe: 36 months

Interventionmcg/L (Mean)
Placebo2.3
Toremifene 20mg2.0

[back to top]

The Effect of Toremifene on the Mean Change at 36 Months in AUA (American Urological Association) Symptom Score

To assess the effect of toremifene on the AUA (American Urological Association) symptom score mean change from baseline. Scores of 0-7=mild severity, 8-9, moderate, and 20-30, severe with possible responses of 0 (not at all) 1 (<1/5), 2 (<50% time), 3 (about 50% time), 4 (> 50% time) & 5 (Almost Always). There are 7 questions (1)Incomplete emptying (2)Frequency (3)Intermittency (4)Urgency (5)Weak-stream (6)Straining & (7)Nocturia. Analysis is change from baseline at final evaluation (36 months) for quality of life due to urinary symptoms. The P Value is from a Wilcoxon signed-rank test. Scores can range from 0-35, highest representing worse symptoms (NCT00106691)
Timeframe: 36 months

Interventionscores on a scale (Mean)
Placebo1.1
Toremifene 20mg1.2

[back to top]

The Effect of Toremifene on Total PSA (Prostate Specific Antigen) Levels

To assess the effect of toremifene in the total PSA (prostate specific antigen) levels from baseline (NCT00106691)
Timeframe: Up to 36 months

Interventionmcg/L (Mean)
Placebo0.82
Toremifene 20mg1.07

[back to top]

Occurrence of High Grade PIN at the 12, 24, 36 Month Biopsies

To measure the occurrence of high grade PIN at the 12, 24, 36 Month intervals in the 360 days study. (NCT00106691)
Timeframe: Up to 36 months

,
InterventionSubjects (Number)
12 months24 months36 months
Placebo1679092
Toremifene 20mg14910394

[back to top]

The Effect of Toremifene on Hormone Levels

% Change from baseline hormone levels, including total testosterone, free testosterone, dihydrotestosterone (DHT) and estradiol (NCT00106691)
Timeframe: Up to 36 months

,
Intervention% of change (Mean)
DHTEstradiolTestosterone totalTestosterone free
Placebo17.73611.92.24617.71
Toremifene 20mg46.40953.231.1367.92

[back to top]

The Effect of Toremifene on Lipid Levels

Measure lipid levels including total cholesterol, LDL, HDL and Triglycerides % change from baseline (NCT00106691)
Timeframe: Up to 36 months

,
Intervention% of change (Mean)
CholesterolLDLHDLTriglycerides
Placebo-3.678-7.4473.6916.298
Toremifene 20mg-6.675-7.8240.290.319

[back to top]